Oncternal Therapeutics, Inc.
ONCT · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -47.3% | -65.5% | 27.9% | – |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | -3,690.2% | 88% | 96.1% | -255.6% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 284.7% | -3,016.6% | -722.2% | -515.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5,029.2% | -2,912.3% | -725.4% | -509.9% |
| EPS Diluted | -13.43 | -16.5 | -1.94 | -0.69 |
| % Growth | 18.6% | -750.5% | -181.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |